MENU
+Compare
GIKLY
Stock ticker: OTC
AS OF
Sep 4 closing price
Price
$7.14
Change
-$0.35 (-4.67%)
Capitalization
8.66B

GIKLY stock forecast, quote, news & analysis

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more

GIKLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GIKLY showed earnings on July 29, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for GIKLY with price predictions
Sep 05, 2025

Momentum Indicator for GIKLY turns negative, indicating new downward trend

GIKLY saw its Momentum Indicator move below the 0 level on August 27, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 68 similar instances where the indicator turned negative. In of the 68 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GIKLY turned negative on August 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

GIKLY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 176 cases where GIKLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.612) is normal, around the industry mean (9.473). P/E Ratio (27.835) is within average values for comparable stocks, (24.006). Projected Growth (PEG Ratio) (0.236) is also within normal values, averaging (1.780). GIKLY has a moderately low Dividend Yield (0.012) as compared to the industry average of (0.028). P/S Ratio (1.081) is also within normal values, averaging (3.466).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GIKLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GIKLY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

A.I.Advisor
published Dividends

GIKLY paid dividends on August 20, 2025

Grifols Sa GIKLY Stock Dividends
А dividend of $0.09 per share was paid with a record date of August 20, 2025, and an ex-dividend date of August 12, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 90.27B. The market cap for tickers in the group ranges from 72.83K to 651.91B. LLY holds the highest valuation in this group at 651.91B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 10%. SCLX experienced the highest price growth at 28%, while PTKFF experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was -34% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 70
Price Growth Rating: 55
SMR Rating: 61
Profit Risk Rating: 78
Seasonality Score: -33 (-100 ... +100)
View a ticker or compare two or three
GIKLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Avinguda de la Generalitat, 152
Phone
+34 935712200
Employees
23744
Web
https://www.grifols.com